Nasdaq Approves Listing of Canary’s Staked Injective ETF

Cointime update: Nasdaq has approved the listing of Canary’s staked Injective ETF, the proposed INJC fund. The fund would stake at least 90% of its INJ holdings and charge a 1.10% annual sponsor fee. The approval marks a step toward bringing a yield-bearing staking product for the Injective token to U.S. exchanges.